Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib in Invasive Breast Cancer
NCT01934335Phase 2Terminated
- Sponsor
- Ronald Weigel
- Start
- Oct 2013
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vandetanib in Invasive breast cancer (IBC), sponsored by Ronald Weigel. Started Oct 2013; status: terminated.
02
Drugs
vandetanib
03
Conditions
Invasive breast cancer (IBC)
Beyond the preview
Go deeper on NCT01934335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01934335.